United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hydrochloride, usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hydrochloride, usp are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride, usp, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride, usp. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be mo

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the

United States - English - NLM (National Library of Medicine)

hospira, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hcl injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. dopamine is contraindicated in patients with pheochromocytoma. risk summary there are no human data with dopamine use in pregnant women. there are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated (see clinical considerations ). in animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine hcl administration in pregnant rats during organogenesis at doses, on a mcg/m2 basis, of one‑third the human starting dose of 2 mcg/kg/minute (90 mcg/m2 /minute). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies carry some risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2‑4% and 15‑20%,

United States - English - NLM (National Library of Medicine)

hospira, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 0.8 mg in 1 ml - dopamine hydrochloride in dextrose injection is indicated to improve hemodynamic status in patients in distributive shock, or shock due to reduced cardiac output. dopamine is contraindicated in patients with pheochromocytoma. risk summary there are no human data with dopamine use in pregnant women. there are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated (see clinical considerations ). in animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine hcl administration in pregnant rats during organogenesis at dosages, on a mcg/m2 basis, of one-third the human starting dosage of 2 mcg/kg/minute (90 mcg/m2 /minute). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies carry some risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregna

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 80 mg in 100 ml - dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the

United States - English - NLM (National Library of Medicine)

cardinal health - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride, usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hydrochloride, usp are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride, usp, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride, usp. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. clinical studies have shown that when dopamine hydrochloride, usp is administered before urine flow has diminished to levels of approximately 0.3 ml/minute, prognosis is more favorable. nevertheless, in a number of oliguric or anuric patients, administration of dopamine hydrochloride, usp has resulted in an increase in urine flow, which in some cases reached normal levels. dopamine hydrochloride, usp may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. it should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. low cardiac output – increased cardiac output is related to dopamine’s direct inotropic effect on the myocardium. increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. increase in cardiac output has been associated with either static or decreased systemic vascular resistance (svr). static or decreased svr associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension – hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine hydrochloride, usp which have little effect on svr. at high therapeutic doses, dopamine’s alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished svr. as in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. therefore, it is suggested that the physician administer dopamine hydrochloride, usp as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. dopamine hcl should not be used in patients with pheochromocytoma. dopamine hcl should not be administered to patients with uncorrected tachyarrhythmias or ventricular fibrillation.

United States - English - NLM (National Library of Medicine)

cardinal health - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine. patients most likely to respond adequately to dopamine are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine, the better the prognosis. urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusio

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride in 5% dextrose injection, usp is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. when indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. poor perfusion of vital organs: although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 ml/minute prognosis is more favorable. however, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. the drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. low cardiac output: dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. increased output has been associated with unchanged or decreased systemic vascular resistance (svr). the association of static or decreased svr with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension: low to moderate doses of dopamine, which have little effect on svr, can be used to manage hypotension due to inadequate cardiac output. at high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished svr. as in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. dopamine hydrochloride should not be used in patients with pheochromocytoma. dopamine should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillation. to open tear outer wrap at notch and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. preparation for administration (use aseptic technique) 1. close flow control clamp of administration set. 2. remove cover from outlet port at bottom of container. 3. insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. 4. suspend container from hanger. 5. squeeze and release drip chamber to establish proper fluid level in chamber. 6. open flow control clamp and clear air from set. close clamp. 7. attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. 8. regulate rate of administration with an infusion pump, preferably a volumetric pump. warning: do not use flexible container in series connections.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - dopamine hydrochloride, quantity: 200 mg - injection, concentrated - excipient ingredients: sodium chloride; potassium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - for the correction of haemodynamic imbalance present in: acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. as an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia. in chronic cardiac decompensation as in congestive failure.